Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano

Milan 22162

1 studies enrolling now · 6 studies all time

What they study most

B-Cell Malignancies, CRC (Colorectal Cancer), Endometrial Cancer, Follicular Lymphoma, Marginal Zone Lymphoma, Metastatic Cholangiocarcinoma, Squamous Cell Carcinoma of the Anal Canal, Unresectable Cholangiocarcinoma

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer — Recruiting now
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. — Completed
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). — Completed
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early